Journals disclose Cuban contributions to fight against Covid-19
especiales
The article refers to the results of a study that combined the timely use of Itolizumab with other antiviral and anticoagulant therapies to reduce the worsening of Covid-19 disease and mortality.
'The humanized Itolizumab antibody emerges as a therapeutic alternative for Covid-19 patients and suggests its likely use in others with cytokine release syndrome due to other pathologies,' the text indicates.
It is an innovative product of Cuban Biotechnology, which according to experts allowed reducing the number of patients with evolution to critical stages.
Among those who benefit from this treatment, the elderly with multiple comorbidities stand out, who are particularly susceptible to adverse clinical results in the course of infection by the SARS-CoV-2 virus, which causes the Covid-19 disease.
Add new comment